Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND studyKristian Reich, Claire Clibborn, Norito Katoh et al.|Journal of the European Academy of Dermatology and Venereology|2023Cited by 47
Abrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension <scp>JADE EXTEND</scp> studyKristian Reich, Claire Clibborn, Jonathan I. Silverberg et al.|Journal of the European Academy of Dermatology and Venereology|2023Cited by 9